<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36106861</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>5-6</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>ALSUntangled #67: rituximab.</ArticleTitle><Pagination><StartPage>544</StartPage><EndPage>547</EndPage><MedlinePgn>544-547</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2022.2122845</ELocationID><Abstract><AbstractText>ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS who ask about them. Here we review rituximab, a drug which specifically depletes B lymphocytes. We show a current lack of evidence for a role of these cells in ALS progression. The one patient we found who described using Rituximab for their ALS found no benefit. Given all this, and the known serious risks of rituximab, we advise against its use as an ALS treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armon</LastName><ForeName>Carmel</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Loma Linda University, Loma Linda, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barkhaus</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical College of Georgia, Augusta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4241-5135</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertorini</LastName><ForeName>Tulio</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Neurology Department, University of Tennessee Health Science Center, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bromberg</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>Gregory T</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crayle</LastName><ForeName>Jesse</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurology Department, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimachkie</LastName><ForeName>Mazen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kansas, Kansas City, KS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Eva L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goslinga</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heiman-Patterson</LastName><ForeName>Terry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Temple Health, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jhooty</LastName><ForeName>Sartaj</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lichtenstein</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Avram and Stella Goren-Goldstein Biotechnology Engineering Department, Ben-Gurion University of the Negev, Beer-Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lund</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Undergraduate, Green Hope High School, Cary, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mcdermott</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1269-9053</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pattee</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pierce</LastName><ForeName>Kaitlyn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratner</LastName><ForeName>Dylan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Undergraduate, Longmeadow High School, Longmeadow, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>Kristiana</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Montreal Neurological Institute, Montreal, CA and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wicks</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-2293-9284</Identifier><AffiliationInfo><Affiliation>Independent Consultant, Lichfield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedlack</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056687" MajorTopicYN="N">Off-Label Use</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">off-label treatment</Keyword><Keyword MajorTopicYN="N">rituximab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36106861</ArticleId><ArticleId IdType="doi">10.1080/21678421.2022.2122845</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>